Anti-Ganglioside Antibodies in New Onset Type 1 Diabetic Patients and High Risk Subjects

References

• Hakomori S. Glycosphingolipids in cellular interaction, differentiation and oncogenesis. Annu. Rev. Biochem. 1981; 50: 733–764
   PubMed Web of Science ®Google Scholar
• Endo T., Scott D. D., Stewart S., Kundu S. K., Marcus D. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J. Immunol. 1984; 32: 1793–1797
   Google Scholar
• Hirano T., Hashimoto H., Shiokawa Y. Anti-glycolipid autoantibodies detected in the sera from systemic lupus erythematosus patients. J. Clin. Invest. 1980; 66: 1437–1442
   PubMedGoogle Scholar
• Gillard B. K., Thomas J. W., Nell N. J., Marcus D. M. Antibodies against ganglioside GT3 in the sera of patients with type 1 diabetes mellitus. J. Immunol. Methods. 1989; 142: 3826–3832
   Google Scholar
• Castano L., Eisenbarth G. S. Type 1 diabetes: a chronic autoimmune disease of the human, mouse and rat. Ann. Rev. Immunol. 1990; 8: 647–679
   PubMed Web of Science ®Google Scholar
• Atkinson M. A., MacLaren N. K. Mechanism of disease: the pathogenesis of insulin-dependent diabetes mellitus. New Engl. J. Med. 1994; 331: 1428–1435
   PubMed Web of Science ®Google Scholar
• Bottazzo G. F., Florin-Christensen A., Doniach D. Islet cell antibodies in diabetes mellitus with autoimmune poly-endocrine deficiency. Lancet 1974; ii: 1279–1283
   Google Scholar
• Baekkeskov S., Aanstoot H. J., Christgau S., Reetz A., Solimena M., Cascalho M., Folli F., Richter-Olesen H., De Camilli P. Identification of the 64K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151–156
   PubMed Web of Science ®Google Scholar
• Palmer J. P., Asplin C. M., demons P., Lyen K., Tatpati O., Raghu P. K., Paquette T. L. Insuli antibodies to insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337–1339
   PubMed Web of Science ®Google Scholar
• Pietropaolo M., Castaño L., Babu S., Buelow R., Kuo Y.-L.S., Martin S., Martin A., Powers A. C., Prochazka M., Naggert J., Leiter E. H., Eisenbarth G. S. Islet cell autoantigen 69kD (ICA 69) Molecular cloning and characterization of a novel diabetes-associated autoantigen. J. Clin. Invest. 1993; 92: 359–371
   PubMed Web of Science ®Google Scholar
• Castaño L., Russo E., Zhou L., Lipes M. A., Eisenbarth G. S. Identification and cloning of a granule autoantigen (carboxpeptidase H) associated with type I diabetes. J. Clin. Endocrinol. Metab. 1991; 73: 1197–1201
   PubMed Web of Science ®Google Scholar
• Nayak R. C., Omar M. A.K., Rabizadeh A., Srikanta S., Eisenbarth G. S. “Cytoplasmic” islet cell antibodies: evidence that the target antigen is a sialoglycoconjugate. Diabetes. 1985; 34: 617–619
   PubMed Web of Science ®Google Scholar
• Colman P. G., Nayak R. C., Campbell I. L., Eisenbarth G. S. Binding of “cytoplasmic” islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes. 1988; 37: 645–652
   PubMed Web of Science ®Google Scholar
• Dotta F., Colman P. G., Lombardi D., Scharp D. W., Andreani D., Pontieri G. M., Di Mario U., Lenti L., Eisenbarth G. S., Nayak R. C. Ganglioside expression in human pancreatic islets. Diabetes. 1989; 38: 1478–1483
   PubMed Web of Science ®Google Scholar
• Dotta F., Tiberti C., Previti M., Anastasi E., Andreani D., Lenti L., Pontieri G. M., Gianani R., Appel M. C., Eisenbarth G. S., Di Mario U. Rat pancreatic ganglioside expression: differences between a model of autoimmune islet β cell destruction and a normal strain. Clinical Immunology and Immunopathology 1993; 66: 143–149
   PubMedGoogle Scholar
• Dotta F., Peterson L. B., Previti M., Metzger J., Tibreti C., Anastasi E., Zoppitelli P., Wicker L. S., Di Mario U. Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune β-cell destruction. Endocrinology. 1992; 130: 37–42
   PubMedGoogle Scholar
• Svennerholm L. Chromatographic separation of human brain gangliosides. J. Neurochem. 1963; 10: 613–623
   PubMed Web of Science ®Google Scholar
• Vardi P., Dib S. A., Tuttleman M., Connelly J. E., Grinbergs M., Rabizadeh A., Riley W. J., Maclaren N. K., Eisenbarth G. S., Soeldner J. S. Competitive insulin autoantibody RIA: prospective evaluation of subjects at high risk for development of type 1 diabetes mellitus. Diabetes. 1987; 36: 1286–1291
   PubMed Web of Science ®Google Scholar
• Di Mario U., Perfetti R., Anastasi E., Contreas G., Crisà L., Tiberti C., Amendolea M. A., Masala C. Autoantibodies to insulin do appear in non-diabetic patients with autoimmune disorders: comparison with anti-immunoglobulin antibodies and other autoimmune phenomena. Acta Endocrinologica. (Copenh) 1990; 122: 303–308
   PubMedGoogle Scholar
• Boitard C., Bonifacio E., Bottazzo G. F., Gleichmann H., Molenaar J. Immunology and Diabetes Workshop on the Standardization of Cytoplasmic Islet Cell Antibodies. New YorkUSA October, 1987
   Google Scholar
• Senn H. J., Orth M., Fitzke E., Wieland H., Gerok W. Gangliosides in normal human serum. Eur. J. Biochem. 1989; 181: 657–662
   PubMedGoogle Scholar
• Ledeen R. W. The gangliosides. Handbook of neurochemistry, A. Lajtha. Plenum Press, New York 1983; vol. 3: 41–76
   Google Scholar
• Bartholomeusz R. K., Campbell I. L., Harrison L. C. Pancreatic islet A2B5-and 3G5-reactive gangliosides are markers of differentiation in rat insulinoma cells. Endocrinology. 1989; 124(6)2680–2685
   PubMedGoogle Scholar
• Colman P. G., Nayak R. C., Campbell I. L., Eisenbarth G. S. Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes. 1988; 37: 645–651
   PubMed Web of Science ®Google Scholar
• Czarniecki M. F., Thornton E. R. Carbon-13 nuclear magnetic resonances spin-lattice relaxation in the N-acylneuraminic acids. Probes for internal dynamics and conformational analysis. J. Am. Chem. Soc. 1977; 99: 8273–8278
   Google Scholar